Analysis of influencing factors of severity in acute pancreatitis using big data mining

EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases

BACKGROUND

Tremendous opportunities for health research have been unlocked by the recent expansion of big data and artificial intelligence. However, this is an emergent area where recommendations for optimal use and implementation are needed. The objective of these European League Against Rheumatism (EULAR) points to consider is to guide the collection, analysis and use of big data in rheumatic and musculoskeletal disorders (RMDs).

METHODS

A multidisciplinary task force of 14 international experts was assembled with expertise from a range of disciplines including computer science and artificial intelligence. Based on a literature review of the current status of big data in RMDs and in other fields of medicine, points to consider were formulated. Levels of evidence and strengths of recommendations were allocated and mean levels of agreement of the task force members were calculated.

RESULTS

Three overarching principles and 10 points to consider were formulated. The overarching principles address ethical and general principles for dealing with big data in RMDs. The points to consider cover aspects of data sources and data collection, privacy by design, data platforms, data sharing and data analyses, in particular through artificial intelligence and machine learning. Furthermore, the points to consider state that big data is a moving field in need of adequate reporting of methods and benchmarking, careful data interpretation and implementation in clinical practice.

CONCLUSION

These EULAR points to consider discuss essential issues and provide a framework for the use of big data in RMDs.

MiR-181a-5p down-regulates LIF expression to inhibit apoptosis of pancreatic acinar cells

BACKGROUND

Acute pancreatitis (AP) develops rapidly and is often complicated by systemic infections, so early and effective treatment plays a key role in controlling the disease. The mechanism of action and clinical application of microRNAs (miRNAs) in AP have become a hot topic in recent years. Understanding the roles of miRNAs in the development and outcome of AP can help provide new ideas for the diagnosis and treatment of AP.

AIM

To investigate the effect and mechanism of miR-181a-5p on cerulean-induced apoptosis of rat pancreatic acinar cells.

METHODS

The expression of AMY, tumor necrosis factor alpha (TNF-α), and interleukin-6, (IL-6) in rat pancreatic acinar cells induced with cerulein was detected by ELISA. AR42J cells were divided into the following groups: cerulean + anti-miR-con group (transfected with anti-miR-con), cerulean + anti-miR-181a-5p group (transfected with anti-miR-181a-5p), cerulean + si-con group (transfected with si-con), and cerulean + si-leukemia inhibitory factor (LIF) group (transfected with si-LIF). All cells were transfected using liposomes and treated with 15 nmol/L of cerulein for 8 h. Cell apoptosis in each group was detected by flow cytometry. The expression of miR-181a-5p mRNA was detected by qRT-PCR. The protein expression of LIF and caspase-3 was detected by Western blot. The fluorescence activity in each group was detected by double luciferase reporter gene assay.

RESULTS

Compared with the control group, the levels of AMY, TNF-α, and IL-6 increased at 8 h after treatment with cerulein, and the apoptosis rate were significantly decreased (P < 0.05). Compared with the control group, the expression of miR-181a-5p mRNA was down-regulated, and the expression of LIF mRNA and protein was significantly up-regulated in the cerulein group (P < 0.05). Overexpression of miR-181a-5p or knockdown of LIF could inhibit the apoptosis of AR42J cells induced by cerulein. miR-181a-5p can inhibit the fluorescent activity of wild-type LIF cells and negatively regulate the protein expression of LIF.

CONCLUSION

MiR-181a-5p inhibits cerulein-induced apoptosis of AR42J cells via mechanism possibly related to targeting of LIF, which will provide a new direction for the treatment of AP.